Company profile
Tango Therapeutics, Inc.
NASDAQ: TNGX · Healthcare · Biotechnology
#409 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
55CFH 59DQ 44GM 61SS 62
v0.1 · 65/100 weight · provisional
↑ Altman-Z, market scale · ↓ Piotroski F, growth stability
Methodology →Revenue TTM
$57.0M
Rev growth YoY (TTM)
+39.0%
Net income (FY)
-$101.6M
Employees
137
as of 2026-08-08
Market cap
$3.4B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$62.4M$62.4M2025
Net income-$101.6M-$101.6M2025
Operating income-$111.3M-$111.3M2025
Total assets$398.7M$398.7M2025
Liabilities$52.5M$52.5M2025
Equity$346.2M$346.2M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Collaboration Revenue100%
By geography
Not disclosed.
The read
What is Tango Therapeutics, Inc.’s revenue?
Tango Therapeutics, Inc. booked $62.4M in FY2025 revenue, growing 48% year over year — faster than most Healthcare companies we track, at a -162.9% net margin.
Peers · Healthcare
Nuvation Bio Inc.49DDIH Holding US, Inc.——Sorrento Therapeutics, Inc.——Journey Medical Corporation52DFortress Biotech, Inc.62CKestra Medical Technologies, Ltd.——Neighbors
Suffolk →Key facts
CEOMalte Peters
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
ExchangeNASDAQ: TNGX
Employees137
IPO date2020-09-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.